BRPI0518984A2 - anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal - Google Patents

anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal

Info

Publication number
BRPI0518984A2
BRPI0518984A2 BRPI0518984-5A BRPI0518984A BRPI0518984A2 BR PI0518984 A2 BRPI0518984 A2 BR PI0518984A2 BR PI0518984 A BRPI0518984 A BR PI0518984A BR PI0518984 A2 BRPI0518984 A2 BR PI0518984A2
Authority
BR
Brazil
Prior art keywords
treatment
cell proliferation
abnormal cell
viral infections
nucleoside analogs
Prior art date
Application number
BRPI0518984-5A
Other languages
English (en)
Inventor
Dennis C Liotta
Shuli Mao
Michael Hager
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BRPI0518984A2 publication Critical patent/BRPI0518984A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

ANÁLOGOS DE NUCLEOSÍDEO CICLOBUTIL SUBSTITUÍDOS EM 2' E 3'PARA TRATAMENTO DE INFECÇOES VIRAIS E PROLIFERAÇAO CELULAR ANORMAL. São fornecidos nucleosídeos ciclobutil e métodos para seu uso no tratamento de infecções que incluem infecções por Retroviridae (incluindo HIV), Hepadnaviridae (incluindo HBV) ou Flavivirídae (incluindo BVDV e HCV), ou de condições relacionadas à proliferação celular anormal, em um hospedeiro, incluindo animais, e especialmente seres humanos.
BRPI0518984-5A 2004-12-10 2005-12-08 anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal BRPI0518984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63487504P 2004-12-10 2004-12-10
PCT/US2005/044709 WO2006063281A2 (en) 2004-12-10 2005-12-08 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation

Publications (1)

Publication Number Publication Date
BRPI0518984A2 true BRPI0518984A2 (pt) 2008-12-16

Family

ID=36578634

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518984-5A BRPI0518984A2 (pt) 2004-12-10 2005-12-08 anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal

Country Status (9)

Country Link
US (2) US7495006B2 (pt)
EP (1) EP1828145A4 (pt)
JP (1) JP2008523098A (pt)
CN (1) CN101115725A (pt)
AU (1) AU2005313912A1 (pt)
BR (1) BRPI0518984A2 (pt)
CA (1) CA2590115A1 (pt)
MX (1) MX2007006961A (pt)
WO (1) WO2006063281A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
IL151942A0 (en) * 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
CN101115725A (zh) 2004-12-10 2008-01-30 埃莫里大学 治疗病毒感染和异常细胞增殖的2’和3’-取代的环丁基核苷类似物
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
EP2683689B1 (en) 2011-03-07 2017-04-12 Pfizer Inc Fluoro-pyridinone derivatives useful as antibacterial agents
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
EP2694481B1 (en) 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
SI2794628T1 (sl) 2011-12-20 2017-07-31 Riboscience Llc 4'-azido-3'-fluoro substituirani nukleozidni derivati kot inhibitorji podvojevanja RNA HCV
HUE033727T2 (en) 2011-12-20 2018-01-29 Riboscience Llc 2 ', 4'-difluoro-2'-methyl-substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2014186637A1 (en) 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
AU2014272055A1 (en) 2013-05-16 2015-12-24 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
TW201625569A (zh) 2014-11-19 2016-07-16 艾克泰聯製藥有限公司 抗菌性苯并噻唑衍生物
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
CN110049767B (zh) * 2016-10-03 2023-04-04 艾库斯生物科学有限公司 腺苷5′-核苷酸酶的抑制剂
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
CN111194217B (zh) 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855466A (en) * 1987-12-28 1989-08-08 E. R. Squibb & Sons, Inc. Purinyl cyclobutanes
EP0330992A3 (en) * 1988-02-29 1991-11-06 Nippon Kayaku Kabushiki Kaisha Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them
US5126345A (en) * 1988-03-30 1992-06-30 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl triazolopyrimidines
US5130462A (en) * 1988-03-30 1992-07-14 E. R. Squibb & Sons, Inc. Cyclobutane derivatives
US5185459A (en) * 1988-03-30 1993-02-09 E. R. Squibb & Sons Inc. Bis protected (hydroxymethyl)cyclobutanols
IL92096A0 (en) * 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US4918075A (en) * 1988-12-20 1990-04-17 E. R. Squibb & Sons, Inc. Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents
CA2042931A1 (en) * 1990-05-24 1991-11-25 Robert Zahler Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
US5166397A (en) * 1990-09-20 1992-11-24 Nippon Kayaku Kabushiki Kaisha Process for producing optically active cyclobutylamines
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CN101115725A (zh) * 2004-12-10 2008-01-30 埃莫里大学 治疗病毒感染和异常细胞增殖的2’和3’-取代的环丁基核苷类似物

Also Published As

Publication number Publication date
CN101115725A (zh) 2008-01-30
US8114994B2 (en) 2012-02-14
US20060223835A1 (en) 2006-10-05
AU2005313912A1 (en) 2006-06-15
MX2007006961A (es) 2007-10-04
EP1828145A4 (en) 2009-08-19
WO2006063281A2 (en) 2006-06-15
US20090149416A1 (en) 2009-06-11
CA2590115A1 (en) 2006-06-15
WO2006063281A3 (en) 2006-10-12
US7495006B2 (en) 2009-02-24
EP1828145A2 (en) 2007-09-05
JP2008523098A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
BRPI0518984A2 (pt) anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2&#39; e 3&#39; para tratamento de infecÇÕes virais e proliferaÇço celular anormal
BRPI0410846A (pt) compostos, composições e usos para o tratamento de uma infecção por flaviviridae
DK2251015T3 (da) Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
PA8588501A1 (es) Derivados antivirales de nucleósidos
NO20033289D0 (no) Nukleosidderivater som inhibitorer for RNA-avhengig RNA- viruspolymerase
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
TW200500373A (en) 2&#39;-c-methyl-3&#39;-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312278A (pt) éster 2&#39;-c-metil-3&#39;-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
GT199900166A (es) Compuesto quìmico adecuado para usar como agente antiviral.-
DK1265889T3 (da) Lægemidler imod virussygdomme
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
PE20030256A1 (es) Nucleosidos 4 sustituidos como inhibidores de la replicacion del arn del virus de la hepatitis c
BR0307712A (pt) Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
ATE475660T1 (de) Antivirale verbindungen
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
NO20034878L (no) Antivirale forbindelser
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
BRPI0513321A (pt) vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
WO2004062575A3 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
FR2621816B1 (fr) Application antivirale des ologonucleotides
ECSP034699A (es) Compuestos nucleosidos como inhibidores de polimerasa de arn viral dependiente de arn
AR019532A1 (es) COMPOSICIoN FARMACÉUTICA DEL COMPUESTO 1,5-DIDEOXI-1,5-IMIN-D-GLUCITOL N-SUSTITUIDO
TH95730A (th) การใช้อิมมาทินิบเพื่อรักษาความผิดปรกติของตับและการติดเชื้อไวรัส

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.